deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02998385

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) (SANTAL)

A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Conditions HNSCC
Interventions Cisplatin radiotherapy
Updated 14 times since 2017 Last updated: May 6, 2025 Started: Jan 20, 2017 Primary completion: Feb 28, 2030 Completion: Mar 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02998385, this PHASE3 trial focuses on HNSCC and remains ongoing. Sponsored by Groupe Oncologie Radiotherapie Tete et Cou, it has been updated 14 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshot~Jan 2019 – ~Feb 2020 · 13 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Oct 2023 · 18 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

14 versions recorded

  1. Jun 2025 — Present [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE3

  3. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  4. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  5. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

▶ Show 9 earlier versions

  1. Apr 2022 — Oct 2023 [monthly]

    Recruiting PHASE3

  2. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE3

  3. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE3

  5. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  7. Jul 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  9. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Groupe Oncologie Radiotherapie Tete et Cou
  • National Cancer Institute, France
Data source: Groupe Oncologie Radiotherapie Tete et Cou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations